American Society for Transplantation and Cellular Therapy | Strategic Alliance Partners

Experts gather for a roundtable on the rare, delayed toxicities associated with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.

Updated ASTCT infectious disease guidelines reshape approaches to prophylaxis, treatment thresholds, and drug-drug interactions in opportunistic infections.

An RNA- and lipid nanoparticle–based platform derived from non-LTR transposons enables stable in vivo CAR T-cell engineering.

Findings presented at the 2026 Joint ASTCT + EBMT Basic and Translational Scientific Meeting offer potential therapeutic targets to reduce GI toxicity and GVHD.

New findings suggest that differences in immune reconstitution kinetics may drive variations in graft-versus-host disease incidence, infection risk, and overall survival.

Pharmacists unpack CAR T-cell therapy in acute lymphoblastic leukemia, spotlighting obecabtagene autoleucel data and toxicity tips.

Discover the vital role of oncology pharmacists in cancer care, exploring their daily challenges, responsibilities, and impact on patient outcomes.

Oncology pharmacists unpack cGVHD care, highlighting axatilimab’s mechanism, safety monitoring, and team-based strategies to optimize outcomes.

Oncology pharmacists advance multiple myeloma care with BCMA bispecifics and CAR T-cell therapy, improving safety, logistics, and outcomes for American Pharmacist Month.

Experts gathered to discuss the critical need for real-time learning, multidisciplinary collaboration, and comprehensive patient and family support to address unforeseen complications in gene therapy.

Speakers at an ASTCT Gene Therapy Summit highlighted novel conditioning approaches without the use of busulfan, which can cause toxic effects in patients with hematologic malignancies.

Experts at the ASTCT Gene Therapy Summit discussed the multifaceted nature of the gene therapy process for patients with sickle cell disease.